# Rapidly Emerging Antiviral Drug Development Initiative

**READDI**

## Our Mission

READDI seeks to generate new broad-spectrum antiviral therapies to save lives in the current pandemic and to prevent emerging threats from becoming global catastrophes.

## Founding Organizations

The University of North Carolina at Chapel Hill (UNC), the University of North Carolina Eshelman Institute for Innovation (UNC EII) and the Structural Genomics Consortium (SGC).

## Financial Goal

Raise $500 million overall and $125 million for the initial launch of our global nonprofit. This initiative will be staffed by the brightest minds, combining scientific excellence in viral epidemiology with biopharma experience to manage drug development.

## Why READDI?

READDI brings together leaders from industry, government, philanthropic organizations and academic research institutions to leverage existing platforms and accelerate the development of new antiviral drugs.

- The SGC is driving a new scientific and drug discovery ecosystem by focusing explicitly on less well-studied areas of the human genome. The SGC has partnerships with nine global pharmaceutical companies and collaborations with scientists in hundreds of universities globally.

- UNC-Chapel Hill ranks first in U.S. universities for coronavirus research and fifth in the nation in federal research funding. According to U.S. News & World Report, the UNC Eshelman School of Pharmacy is the #1-ranked pharmacy school in the nation and the UNC Gillings School of Global Public Health is the #2-ranked public health school in the nation. The UNC School of Medicine brings more than two decades of virology expertise to the initiative.

- The READDI research model is based on a proven drug research and development model created by the Drugs for Neglected Diseases initiative (DNDi). READDI is actively discussing collaborations with leading academic institutions and pharmaceutical partners. The global access model promotes faster drug discovery, bringing potentially life-saving drugs to market sooner and more cheaply.

## Quick Facts

*Founding Date*
April 8, 2020

*Biopharma Partners*
Calibr
Takeda

*Research/Academic Participants*
READDI is actively discussing partnerships with leading academic institutions, including the University of Washington, Monash University and University College London.

*Key Contributors*
N.C. Policy Collaboratory
Bob ('84) and Tracy ('86) Winston

**readdi.org**